Tofersen and other antisense oligonucleotides in ALS
The advent of antisense oligonucleotide (ASO) therapies in neurodegenerative disorders is associated with enormous hope. Nusinersen treatment was a breakthrough intervention in the recessive disease spinal muscular atrophy, and superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) seems...
Saved in:
| Main Authors: | Albert Ludolph, Maximilian Wiesenfarth |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/17562864251313915 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics of antisense oligonucleotide drugs
by: M. R. Khaitov, et al.
Published: (2013-04-01) -
Antisense oligonucleotides targeting IRF4 alleviate psoriasis
by: Yanxia Yu, et al.
Published: (2025-07-01) -
Antisense oligonucleotides for the arterial hypertension mechanisms study and therapy
by: L. O. Klimov, et al.
Published: (2018-04-01) -
Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis
by: Daisuke Ito, et al.
Published: (2024-12-01) -
Halloysite clay nanotubes as platforms for loading of aptamers and antisense oligonucleotides
by: Maria Rita Caruso, et al.
Published: (2025-03-01)